have come back with a much better offer and astra zeneca have turned it down. what is going to happen now is that it is dependent on what astra zeneca shareholders do next. >> do you think there is a chance that astra zeneca shareholders will turn around and put pressure on the board of the company to go back to the negotiating table to engage again with pfizer? >> there is certainly that possibility. but you have to ask yourself the the astrayou know, zeneca board basically turned the offer down flat. it is hard to imagine they would do that unless they were reasonably confident they had the backing of the majority of the shareholders involved. the ceo has come out this afternoon and said if shareholders don't like what i've done, they can always play someone over me. their votes over me. we will see what happens next. >> was their politics involved, or was this a question of an offer not being big enough for astra zeneca's tased -- ta ste? >> i think it was a combination of the two. i think they were holding up for about 60 pounds per share. but the environme

but astra maintains that still undervalues it. astra may consider bids of around 58 pounds a share.trazeneca shares are down to 42 pounds this morning. before all this starts, we were trading near 30 pounds a share. this potential bids has an awful lot of chat from british politicians. joining us is the secretary of state for business innovation and skills, good morning to you. i presume you are a fairly happy man at the moment if pfizer doesn't come back. they said it's their final offer. and why did you need to get involved in this. shareholders surely can take their own decisions. >> well, i think this firm, in particular, is the second largest farm suit cai pharmaceu. they are so important to innovation and how britain will pave the way in the future. i'm not one who wants to interve intervene and tell companies what to do, but i think as the head of the british chambers of commerce said at the end of last week, being in an open economy does not necessitate saying yes to every merger. there were people in the science community who had grave concerns that proposed takeover by pfi

astra's board will meet to discuss the offer. >>> and rbs shares soar to the top of the market in london. >>> and reports of casualties roll in as kiev launches a military operation to gain control in the east. the country's prime minister warns ukraine is entering its most dangerous ten days since independence. >>> and the u.s. economy is expected to show one of the biggest gains in hiring in months in april. with companies in all sectors putting out the help wanted signs. >>> you're watching "worldwide exchange," bringing you business news from around the globe. >>> a warm welcome to today's

in an effort to create the world's largest pharmaceutical company pfizer had been chasing astra zeneca since away back in november now pfizer last proposed a deal for the company in november valued at one hundred twenty eight billion dollars billion with a b under u.k. takeover rules astra zeneca was able to run out the clock on monday's deadline for reaching an agreement the decision ends a month long public fight between two of the world's biggest pharmaceutical companies the battle sparked political concerns on both sides of the atlantic over jobs and corporate tax maneuvers british rules now require enforced cooling off period astra zeneca could reach out. pfizer after three months and pfizer could take another run at its smaller british rival in about six months now pfizer walked away from the table with two hours to spare on monday morning and its decision to abandon negotiations had been widely expected after astra zeneca refused its final offer of ninety two dollars a share pfizer c.e.o. ian reid said in a written statement quote we continued to believe that our final proposal

it is quite clear that astra has done some downsizing too.ompared to the track record of pfizer and with the limited commitment they have to research and development, i am worried that we would see downscaling. astrazeneca is still a very important swedish companies -- company. it is one of our major exporters and taxpayers. the merger with astrazeneca has worked quite well. company that has had a strong presence in our market and we are quite worried that pfizer, an american company, the move out of our region. i think we have a stake in this. we have put money into life science research. we are paying for a lot of the pharmaceuticals that they are providing. we are worried that this would mean job losses not only in sweden, but in the u.k. if you see a negative reaction today -- >> carry on. i am sorry. was trying to say that if you would see a negative reaction today and tomorrow from the british government, the british political system, i am quite certain that pfizer would not push through with this deal. hostile takeover notthe benefits

in terms of pfizer and astra's point, this government has been absolutely clear that the right thing to do is to get stuck in the best possible guarantee on british jobs, british investment and british science. we discussed this last week and one of the most important things we learned since last week is the right hon. gentleman was asked for a meeting with pfizer but he said he was too busy political campaigning. t quite literally put politics ahead of the national interests. >> i won't take any lectures from the guy who was negotiating, negotiating with pfizer over the board of astra's an act that. pfizer picked off the prime minister. members on all sides of the house, the appearance of pfizer and the select committee raised more questions than it answered about a so-called assurances. the head of pfizer, research and development spending as a result of the takeover. has the prime minister got an assurance that these cuts will not take place in the u.k.. the strongest possible guarantee, what is the way of getting those guarantees? is it getting stuck in with pfizer and astra's ze

astra's board is discussing the offer.tations out of the water, a big jump in profit, shares at the top of the london market. reports of casualties roll in as kiev launches a military operation to regain control in the east. the country's prime minister warning ukraine is entering its most dangerous ten days since independence. plus the u.s. economy is expected to show one of the biggest gains in hiring in months for april. the companies in all sectors putting out the help wanted signs. >>> you're watching "worldwide exchange," bringing you business news from around the globe. >>> and if you just joined us this morning, welcome to your trading day here on cnbc and "worldwide exchange." it's going to be really all about the jobs number before we get doing today. ahead of that, the futures are indicating a slight tick higher but it will all change at 8:30 eastern. the forecast is for an average of 215,000 nonfarm payroll jobs to be created for the month of april. european equities ahead of that have been a little bit firmer

where astra will share its latest findings.me and the interpretation of those -- will determine the future of this saga. build onnk astra can the momentum it has demonstrated? can it deliver on the promises within its pipeline? >> i think mostly for the industry it feels --if they have been able to people truly buy into that. when and if they can meet future production is -- still depends on the outcome. there is a sense that there is a culture change here. foro think it was a mistake astrazeneca not to sell? a lot of people were seeing this was a very good price. it was a 40 five percent premium versus the price of astra zeneca shares when the news broke. you think astra zeneca mistake here? down to thet boils investment. obviously, the board is making the case that the future of astrazeneca as an independent game -- as an independent company outweighs the short-term gain of profit. certain shareholders support the board and others are more frustrated. that is basically how things the, depending on investment. >> what would yo

coming up, astra seneca's chairman.'s last and final pitch we will be right back. weekdays are for rising to the challenge. they're the days to take care of business. when possibilities become reality. with centurylink as your trusted partner, our visionary cloud infrastructure and global broadband network free you to focus on what matters. with custom communications solutions and responsive, dedicated support, we constantly evolve to meet your needs. every day of the week. centurylink® your link to what's next. life with crohn's disease ois a daily game of "what if's". what if my abdominal pain and cramps come back? what if the plane gets delayed? what if i can't hide my symptoms? what if? but what if the most important question is the one you're not asking? what if the underlying cause of your symptoms is damaging inflammation? for help getting the answers you need, talk to your doctor and visit crohnsandcolitisinfo.com to get your complimentary q&a book, with information from experts on your condition. [ male announc

astra asen rejected by an adequate. as a company. -- it has been rejected by astrazeneca as inadequate. offer and their last they would not go hostility to negotiate a deal as a date. may, could they squeeze out another offer? no opening price yet on astrazeneca. essence you get an opening price on the stock, we will bring it to you that as soon as we get an opening price on the stock, we soon as we gets the opening price on the stock, we will bring it to you. markets,n the equity the futures are a little low. this is the opening. 0.1%.up by despite the bad today to last -- the stoxxe in 600, the benchmark up for a fifth straight week of agains -- gains. looking at stocks. today could be the day will we get information from credit suisse on the find from you as regulators expected to be around two point $5 billion. will it, with a guilty plea? 5- expected to be around $2. billion. with a guiltye plea? easing the next month. expectations are high. this is from the bank. if they are too strong, you are too weak. right abo

takeover court in combination with astra zeneca.t going to report the diluted guidance that there are reporting other guidance. that is the specific wording of their outlook. >> as we heard in the last hour, the top rated -- this is all about pfizer getting closer to cancer drugs, which it would get reasonably by buying astra zeneca. astrazeneca has denied the bit twice. >> i go down to the basics. >> viagra. to let us know o le you don't need it. >> it continues to see buybacks of $5 million -- of five dollars per share. to other headlines. another recall for general motors. thattime it is 52,000 suvs flawed a fuel gauge software. gm is being investigated over why it took so long to recall 2.5 million cars with faulty ignition switches. siemens is on the verge of selling its airport units. this is according to people familiar with the talks. siemens makes partial unit baggage handling systems. win.g on the win comes months after city created a unit that combines custody with financing and fund services. that is this morning's compa

astra shares down 2%.an reid, the pfizer ceo blaming takeover rules as part of the reason the deal failed. >> thank you, geoff. >>> evolving technology and caught this online and thought we needed to show it to you. take a look. >> this would be the hardest thing in the world. >> what you need to do is type the word print first. >> oh. >> that has nothing to do with print. >> i don't get how you have to put print -- nothing prints out. >> print. oh. >> oh! it did it. i feel so proud of myself. >> finally! took a thousand years. >> you remember that? we'll have more from these kids comes up later. the technology that originally impressed you but now in behindsight seems kind of lame, tweet us your most creative answers using the 'stache #waytooearly. >>> did the heat take control? >>> the match made in paparazzi heaven. the can't miss details from kim and kanye's nuptials including the celebrity who came dressed as batman. that story and a chick on weather when "way too early" comes right back. you already

astra zeneca got a boost. one of the biggest institutional stockholders.hers -- they say that after zeneca will earn better returns for shareholders by staying independent. blade market is dominated by gillette. one is trying to dethrone these companies. david tweed has the story. in the small town in the a new east germany, york-based startup is making waves. >> my name is andy katz-mayfield. wem the cofounder of harry sell our own products through our website. there are companies that have been part of the industry for a long time. they charge prices that are disconnected from the cost of manufacturing. was $100tal cost million. we searchedd and all over the world to find the best manufacturer. it turns out the best manufacturer in the world is in germany. we are able, particularly owning a factory, deliver a product efficiently to our customers. we get it directly to them. by doing that, we deliver it at an exceptional value. mean,t down here and, i you walk through the factory and immediately have an appreciation for how hard it is to actually manufact

i think if pfizer increases the price, then the chances are there the astra board could renew talks. really see it happening. >> i'm going to preach a question that mark put to our guest earlier on in the show, which is simply, do you think astrazeneca is making too much of these new promising oncology drugs they have in the pipeline, they said that is the reason pfizer doesn't have the price right because those drugs are really going to deliver more value? it is not only oncology. oncology looks very interesting. i would say it is difficult to asteriskse drugs, but --lly really hasn't shown hasn't shown good results. you have diabetes, autoimmune diseases, so i think -- and on top of that, you have three options in very high risk areas like alzheimer's, which i don't think anyone attaches any value to now, but obviously, that is something on top of that shareholders -- astrazeneca shareholders could potentially benefit from. is not only oncology. >> thank you for joining us, health-care analyst and portfolio manager. >> and from farmer to football, the world cup kicks off next month

astra zeneca says the bid is not enough. to 60 raises the bid billion pounds before being turned down once again. game over or not? >> i've talked to one of my andnds on the sell side they have talk to the company directly and it sounds like they do not want to carry on business. it is not just about the price. there talking about social responsibility. that resonates very well with the political climate and the way this has been handled in the public domain. i think it is done for now. i don't know how many more degrees of freedom pfizer has in terms of its movements, at least for the next three to six months. >> what are pfizer's options here? there are no other big pharma companies for them to buy. >> i don't know whether you would call it hostile if they try to reach out to shareholders. i don't know if that qualifies as hostile. there is still four trading days left -- are still four trading days left. they could sit around the table and figure out -- of -- they have kind of sat around the imaginary table. >> the two-ho

drugmaker, has abandoned its efforts to take over the british pharmaceutical company, astra zeneca. pfizer withdrew its latest unsolicited offer of nearly 120 billion dollars. astra zeneca's board rejected pfizer's offers four times over the past few weeks, saying the bids were not high enough. pfizer would not say if it will try again... but industry analysts expect another move in a few months... after a mandatory three-month waiting period. time for sports. a year ago, the blackhawks were down three- one to detroit before winning three straight to advance in the playoffs... now they'll have to do it again. patrick kane moved to the top line with jonathan toews in game four. hawks on the power play early... marian hossa makes a nice move in front but jonathan quick makes the save... hawks went oh- for- three on the power play still scoreless later in the period and a kings' power play now... corey crawford gets screened and jake muzzin scores his fifth of the playoffs. hawks down two later in the period... kings on another power play and dustin brown scores on the wide open net. b

casts doubt on whether his approach for astrazeneca could be described as a foreign takeover, saying astra has a huge presence in the u.s. astrazeneca's response says the firm has attractive growth prospects and momentum as an independent company. the chairman also welcomed the effort of the management team over a period of uncertainty. katherine boyle joins us to talk more about this. so walking away with a bit of a bitter taste in his mouth in taking a swipe at the uk government as he does it. >> absolutely, julia. there's a rocky early courtship for astrazeneca and pfizer. it's definitely gone a bit bad romance. what you've got is a testy statement from ian read, criticizing astrazeneca management and the uk government, generally coaching it in terms that are quite bad tempered. having said that, that doesn't mean pfizer won't necessarily come back to the table for astrazeneca. they have three months in which they can try and woo sha shareholde shareholders, obviously while sticking within the complicated takeover reels. if astrazeneca management are persuaded enough, they could come ba

obviously no one else being officially investigated yet. >> very briefly, we mentioned astra and pfizerbe different today from yesterday's hearings? >> they had to focus on the research angle and particularly what could happen to some of astrazeneca's new drugs. he's really been keen to refute the claims by astrazeneca chief executive yesterday. some of astrazeneca's really important new drugs might not get to market in the time he could. he's also stressed the importance of the length of development pipelines to this deal and how difficult it is to plan for ten years in advance when you just don't know how medicines will tornado out. >> which is why you need to plan for 20 years, right? kaj lynn, thank you for that. >>> we head through a weaker european trading session so far. a gain for the u.s. markets yesterday, ending on record highs. for these futures, relatively unchanged and similarly for the nasdaq losing around 0.3% in net trading yesterday. we saw the russell, down just over 1% in yesterday's trading session. we saw a cluster of u.s. listed stocks hit. right before the closin

astra could be a potential target the company. >> it could be.yer and any deal would have to be on favorable terms. i am not sure that any drug company is ready? >> you like insurers. you favor them. have both cases, they long-term supplies of minerals and strong geographic positions. a good supply in the chinese despite the recent fear over chinese growth. reacheddemand inc. usage of metals and, consequently, they have had a long run as of late. would you be rushing into japan, like last year? optimistic on japan. nothing is expected tomorrow. why by japan? >> people are getting carried a way. we have. i would say to you that the japanese authorities are aware of the opportunity for this government to do something meaningful to the economy. i see a package forthcoming in the summer. there is a weaker yen. >> it has been on the move for a long time. it moved a lot. confident that the climb will resume. consequently, it will give the catalyst that people need to return to the market that is not correlated with other western markets. you have diver

with a sweetened offer in terms of the cash element of it, this is battle up to the real to convince astra. >> that is one battle. the other, we're hearing fascinating stuff about what they want to do here. they are assuring the dwovet of their long-term commit to the u.k.. pfizer is a company that recently pulled out of parts of the southeast of england with the loss of a few thousand jobs. that won't have been forgotten by the u.k. government. >> jobs. we had the c.e.o. from pfizer originally saying that he would not guarantee jobs. >> what they are guaranteeing for the moment at least is that they are going to be tax residents in the u.k.. that is good news. >> here is a pretty important line swl, anna. 20% of the combined total or the research and development workforce in the u.k. going forward. the reason why that catches my eye is one of the big arguments, on bloomberg this morning, is that when pfizer did the deal with wyat in 2009, they closed own nearly $5 billion of r & d business. since the year 2000, they have spent over $240 billion on m&a d produced three blockbuster drugs. t

pharmaceutical giant astra zeneca. this is about 35 minutes. >> order. questions for the prime minister. jonathan edwards. >> number one, mr. speaker. >> thank you, mr. speaker. this morning i had meetings with colleagues and others and in addition to my duties, i shall have further such meetings later today. >> u.k. has 104 billionaires. london has 72 billionaires, top city in the world. is the prime minister concerned? that most of our people are getting filthy rich? >> what is worth while is the massive fall in unemployment and increasing employment that we have seen across our country. in terms of wales today, unemployment has fallen by 5,000 and fallen by 25,000 since the last election. that means in wales, 59,000 more people in work. in terms of making sure that the richest in our country pay their taxes, actually we see the richest 1% paying a greater percentage of income tax than ever they did under labour. what we are seeing is a broad-based recovery and i want to make sure everyone in our country can benefit and we are cutting people's taxes an

cofferdam hundred and $18 billion for astra's on a cut.o a said yesterday at the offer is final and they will walk away from merger talks. the merger would increase the world's largest drug company. >> and happiest place on the wrist just a bit more expensive. >> disneyland now rising ticket prices. entrance fees for disneyland park or california at venture will now cost visitors $96. >> the hawks are undefeated at home. >> 1.9 goals but >>> the hawks hosting the kings. the kings will go on to tie it. flair as a long shot that deflected off with a defenseman. >> >> crawford made 25 saves. >> similar to the minnesota serious we can try and generate a little bit more shots coming off tonight. >> >> the bears are going to be holding onto their star receiver for a few more years. >> the deal keeps the pro bowler with the team through the 2017 season. >> marshall who battles and personal disorder says it plans to donate $1 million to a mental health community. >>. socks going for a series when. takes him deep to left for a solo shot. >>2 >> >>

. ♪ astra zeneca shares takeover bid is too low. buying directv for $50 billion.nk enlists in a m. -- capital hike. morning to our viewers. >> good m

so much the u s drugmaker pfizer has offered to buy its british rival astra the senate after sleeping an earlier offer astrazeneca says that price on your values. this center will set fees increased and that the takeover could lead to job cuts a key research facilities. market watchers are wondering if pfizer will make a post on that you know from a business size masses one of prizes blockbuster product is the male potency drugs viagra. but to stay on top companies need huge financial resources to winter events like drunk patrons expiring. all authorities refusing to license drugs that cost billions in research and development costs in the industry are enormous. with its bid to buy astrazeneca find someone to keep growing. astrazeneca has rejected three office and pop singer day undervalued the company. there's a lot at stake. today no boxes of switzerland is the world's biggest pharmaceutical company funded by us rival pfizer not. astrazeneca is commenting on the seventh tie up between cries and astrazeneca would create the new number one the pharmaceuticals industry is experiencing

second which is the flawless and rescue operations began so hopefully more progress can be made and astra now dry weather warnings remain for areas along the eastern coastal regions. the humidity level and tackle has dropped to thirty one percent though please be on the lookout at the fire danger level is high thinking i might get the kind conditions and sale of high pressure system from the west sea where seem fairly clear skies across the back. now tomorrow is shaping up to pee at night then sunny day. accordingly because there will be a big gap in temperatures between today and i are taking up other leg at friday's reading of holiday wouldn't want you all hit their mid twenties well with antique that twenty two. holding on to other place they've said it tops out at twenty two degrees while to do and not conduct the debate team. that's all for now but don't forget to tune in for mark to midnight and that brings are broadcast on prime time news to close this thursday thanks for watching enter this again tomorrow. i was and jason kelly from hong kong and in general and for me to leave can

he dealt with job losses in the wake of the astra and zenecz merger 15 years ago.erspective. stay with us. ♪ >> time for today's company news. germany's largest steel maker reported its first quarterly profit in almost two years after selling assets and cutting costs as it focuses on its non-core business. the company's last reported profit was for the third fiscal quarter of 2012. socgen says it will seek to increase return on equity to more than 10% by 2016, helped by lending in africa. they see consumer growth both in russia and africa rising by 7% annually on average over the next three years. that would be outpacing growth at its french princes -- french branches. ae ceo of unicredit said diplomatic solution to the crisis in ukraine is needed to protect a business in europe. >> i hope that, at the end of the day, common sense will prevail on both sides. russia, we need to find a solution. solution, itfind a is going to impact european business, including europe and russia. let's welcome back to "countdown ." minutes in london, 14 until the start of equity trad

might -- thethe tax policy value equation -- he said absolutely, that is something astra zeneca shareholdersnsated for, the potential risk. qwest thank you for bringing us the interview with the chairman of astra zeneca in the wake of the rejection. >> indeed. today, we had quite a few hours speaking to katie couric. she is taking the fed up challenge, no sugar. i will try. .omorrow, we will talk to a guy his request to go after chinese mobile service. it is only getting bigger. it has now delayed the filing of his annual report a second time. it is only getting hotter. thank you so much for watching. it is 56 past the hour. blumer television is taking you on the markets. the chief markets correspondent has more. qwest thank you. cypher k's options insight. bit of a bounce back, currently leaving the market higher. indicate?tions are they ready to make another run in 1900? >> interesting developments in the options market last week, specifically volatility. sharp declines at the beginning of the week and toward the week, as equities sold off, there were prints expecting volatility to move hi

astra has to decide that they want to welcome pfizer back to the table..way with no we offered a full and fair value. that was ian reeves comments to the british press. that is the drug story. let's turn our attention to china and the chinese government. the are said to be pushing -- our correspondent has the story from berlin. hans, this marks a clear escalation in a dispute with the u.s. over spying. is it tit-for-tat or is it becoming something much more substantial? word, that would be substantial. iesn you look at the compan that portfolios in both companies, we are talking about huge businesses. this move from the chinese government and what they're asking the banks and financial institutes to do is consider switching their servers, getting rid of the ibm servers. as according to four people familiar with the matter. some great reporting from our chinese colleagues. this comes after the indictment by the u.s. department of justice of five army officers who were indicted for potentially stealing cyber secrets from companies like anda and u.s. steel w

astra ejected the bid on friday. chinese yuan retailer wants to give a group of insiders exclusive rights to nominate a majority of the board. alibaba plans to give all shares equal weight as a result. we will take a break. see you in a moment. ♪ >> welcome back. you are watching "the pulse. go space innovation. elon musk has been leaving a push to reach space. we got a look at in nasa competition deciding who will build america's next shuttle. time we were racing into space, it was about national pride. >> the eagle has landed. >> this time, its about money. the international space station is a near zero gravity laboratory dedicated to scientific research. the end of nasa's shuttle program with only one way to get russia. >> is embarrassing that the has left these rights to russia. nasa won't be making it, private companies will. >> we are building this in anticipation of a market emerging. >> nasa is hosting a competition for private enterprise to build a spacecraft to show humans back and forth to low earth orbit.

on the other hand, astra said publicly they are not interested in this hit and they really want stayependent at this stage. therepfizer walks away, is at least a three-month cooling off. period. what happens next to oth parties? >> obviously, it will depend a lot on the performance of astrazeneca over the next few months and the pressure they could have from the orders if do not looks are -- too successful or the of emerging market or japanese is not as high as the market expects. obviously, more pressure from orders. >> is picking up pressure from shareholders, they have to be disappointed the stock fell 10% or more last week on news that the deal was not actually going through. you think that pressure will grow? there is going to be a three-month window. at that point, they could invite pfizer back. if they don't, they have a six-month window. you think astrazeneca shareholders will now be agitating for this deal to go through? again, it is for difficult to say. pretty pfizer gave ambitious targets. they're pretty long-term targets. they could deliver more value to share orders in

if deals like pfizer and astra go through, confidence is back right now. once this goes through, we will see a lot more potential scenarios coming in. in general, it is a great time to be doing deals in europe. there is no guarantee that this will happen. >> is like getting your reception on your sky receiver, mark. you're always wondering whether or not you will get it and you'll be able to see your beloved football team. ans and ruth. >> sunday's secession vote in the east of the country has been denied to as illegal by kiev, by the u.s. and by the eu. moscow, on the other hand, says it respects the will of the people. ryan chilcote has a latest. ryan, and look second overwhelming support for self-rule. what does this mean? there weren't any independent monitors. it really means what russia says it means in some ways. we just heard from the russian foreign minister saying that russia respects the will of the ukrainian people the to pardon his vote. that is different than saying that russia recognizes the results of the vote. he went on to say they did no

that is as much in the interest of astra shareholders than anyone else. if this deal goes through they will receive shares in pfizer as the deal is currently constructed. the big concern people have, in pfizer, you have the largest world pharmacy company which has made since 2003 very big acquisitions. the aggregate value of those companies when acquired by pfizer was in excess of $200 billion. and now, having gobbled up those companies, pfizer is actually worth less. it has a market capitalization that is less than the value of the acquisitions they made. this is the issue that people have worries about. is to what extent, is this going to represent value extraction from a successful british company? yes, of course, astrazeneca, people know, market makers know they've had problem in times past. this is probably one of the two or three companies which will find a cure to cancer in the next few years. people's great worry is they're going to tear the heart out of the company. in particular, it's r&d capacity. it's bad for the company, it's bad for the uk d

the key for me -- >> so buy astra? >> on a long-term basis, i think astrazeneca is excellent value. i am not sure we are going to see any fireworks near term. the rest of the sector are concerned about stretch valuations. >> thank you for putting that into context. james bevan is going to come back. i want to get to one of our top european stories. general electric agreed to give stom time to consider its bid. how much more time? >> three weeks. june 23, two days after the longest day of the year. that is not really relevant, but we always like talking about the summer solstice. here is the issue. as it gives siemens more time to put together their own bid and take a close look at alstom's books? alstom has agreed to this request by the french deadline to extend the deadline. we are hearing a great deal of confidence from ge's ceo. listen to what he had to say on wednesday. actually, read what he had to say. "you have to trust us a little bit that we know what we are doing." the french prime minister has signed a degree -- a decree. ge has sweetened their deal ever so slightly. they

s astra -- astrazeneca says the bid falls short of the company. pfizer says that's it. no more.hey're not going with a hostile bid. the chief business editor spoke to the chairman earlier and started by asking whether the latest offer was closer to the offer the board would exempt? >> it's closer. the frame of reference is 10% or more versus the 53/50 offer. it's been a modest adjustment to that. we're closer on that point. we have greater interests. we are closer. they decided tonight to come out with their last and final offer. primarily this is about how do we deliver drugs to the market in the most efficient way. we are the opinion that is the best way to build shareholder value. it's the best way to really do good for our customers patience and government. if that is jeopardized, we have an issue with that. we were on talks on how best to make sure that didn't happen. now we have the execution risk which is a long while including protection both for our own company, risk for itself and also shareholders in that point of view. finally we look at view of this and weigh in of

astra will fight it, has the government helping them. the board has rejected it. we rather believe pfizer will fail because shareholders will cave. they want the higher price. >> you are an owner of pfizer. it sounds like you have a bad taste in your mouth from this quarter? will you continue to hold those shares or lighten up your position? >> we won't lighten up our position on three months of the year, a five year story of renewal at pfizer in part with astrazeneca. we're not giving up that fast. >> your top health care picks, roach and another. you want to tell us why you like them? >> let's go with roche first. they dominate the world's cancer market. they have a great future, a few patent expirations coming. nothing too awful. we would go with roche, a nice big name. the other is a specialty situation. they recently reported data show their new drug candidate saves lives. the details of that data on in termune. it will be presented at the american thoracic society and think it will make the stock move than it has already moved up about 100%. >> steve weiss h

comes after a bunch of other pharmaceutical deals and pfizer's so-far unsuccessful attempt to buy astraeneca for $106 billion. although i'm guessing that price is going to go. >>> if you're middle class in america, there's almost no room for mistakes. one financial slip and you could fall to the bottom. my look at middle class families trying to rebuild the american dream continues tonight with a single mom putting a brave face on her struggle: >> it's the long, long-term struggle of noting able to have basic needs met. basic needs, as in food in the refrigerator, shoes to work in. >> she's down, but she's not out. i'll tell you how she's giving success one last shot and taking a big gamble with her small business, coming up. >> attracting customers, targeting business opportunities, and finding new business are among the top challenges facing small business owners in the u-s, according to a new gallup survey. but it's kind of according to anybody whoever owned a small gins. jodi bowlin, the owner of a struggling gift shop in knoxville, tennesee is hoping she'll be able to attract new c

the nation's biggest drug maker promised it will not go hostile by taking its offer directly to astra-zeneca'sers. >>> in health headlines this morning america's pediatricians are recommending expectant moms to take a supplement containing iodide. the iodide is needed to make the thyroid hormones required for children's healthy brain development before and after birth. experts recommend pregnant and breast-feeding women get 290 micrograms of iodide per day. one more thing that a pregnant woman needs to take. my goodness, the supplements. >> it's true. i talk to my wife about this because our doctors talk to her, take more iron and things like that. we never heard of iodide. when you think about it is iodized salt. the salt with the umbrella, the woman with the umbrella. but so many people are using kosher salt and others. even when you use take out food. >> it is because of the health scares associated with table salt. you don't want to have heart disease, you don't want to have cholesterol and everything according to the health experts is related to the salt intake. >> seems like there is one

melissa: i am melissa frances with your fox business brief, pfizer is preparing for another run at astra'she ceo told british lawmakers the drugthey could raise its bid while keeping research jobs in britain as the deal went through. he also said he would not be ruling out a hostile bid. also report say at&t is ramping up for multibillion-dollar bid for direct tv, neither side wants to comment that the deal is thought to be around $50 billion. valiant says it is not giving up on a deal with botoxmaker, valium has scheduled a web cast this month to explain to all involved how both companies would be stronger as a team. an unsolicited offer around $46 billion. that is the latest from the fox business network giving you the power to prosper. peace of mind is important when you're running a successful business. so we provide it services you can rely on. with centurylink as your trusted it partner, you'll experience reliable uptime for the network and services you depend on. multi-layered security solutions keep your information safe, and secure. and responsive dedicated support meets your need

comes after a bunch of other pharmaceutical deals and pfizer's so-far unsuccessful attempt to buy astraeneca for $106 billion. although i'm guessing that price is going to go. >>> if you're middle class in america, there's almost no room for mistakes. one financial slip and you could fall to the bottom. my look at middle class families trying to rebuild the american dream continues tonight with a single mom putting a brave face on her struggle: >> it's the long, long-term struggle of noting able to have basic needs met. basic needs, as in food in the refrigerator, shoes to work in. >> she's down, but she's not out. i'll tell you how she's giving success one last shot and taking a big gamble with her small business, coming up. >> on techknow... >> we're heading towards the glaciers >> a global warning >> is there an environmental urgency? >> that is closer than you think... >> even a modest rise, have dramatic impacts on humankind. >> how is it changing the way you live today? techknow... every saturday, go where science meets humanity... >> this is some of the best driving i've ever don

we've gotten offers for pfizer, seeking to buy also ran astra zefrng qaa, and a hedge fund teaming uph cereal acquirer valiant to snap up allergan. david thinks these can be merely a prelude. i think there are many more deals coming in the food, drug, cosmetic, and telecommunications and oil industries. maybe beverages. i'm reluctant to recommend that you sell anything in those categories because of the surge of takeover activity even as i recognize the stocks like kellogg or clorox seem frankly overvalued. i think t-mobile and sprint tie the knot by the end of the month. i checked off a half dozen large independent oils because i suspect the deals in the oil patch and i know these things tend to leak out and people buy calls and they shouldn't, but they do. second positive. there are still whole segments of the market that are still lagging or still cheap. i millmed the big industrials even after the runses. the bank, they're ridiculously cheap if we're about to get any improvement in the economy. same goes for the retailers and they've been held down. the autos, the major all-buying

astra zeneca. i'm jeff glor, cbs news. those little things still get you.dalafil for daily use helps you be ready anytime the moment is right. cialis is also the only daily ed tablet approved to treat symptoms of bph, like needing to go frequently. tell your doctor about all your medical conditions and medicines, and ask if your heart is healthy enough for sex. do not take cialis if you take nitrates for chest pain, as it may cause an unsafe drop in blood pressure. do not drink alcohol in excess. side effects may include headache, upset stomach, delayed backache or muscle ache. to avoid long-term injury, get medical help right away for an erection lasting more than four hours. if you have any sudden decrease or loss in hearing or vision, or any allergic reactions like rash, hives, swelling of the lips, tongue or throat, or difficulty breathing or swallowing, stop taking cialis and get medical help right away. ask your doctor about cialis for daily use and a free 30-tablet trial. natural energy from tea packed with real juice from delicious fruits and veggie

go to school prepared to draw on the lessons here, to search out experienceal opportunities as well astrao to a school with some reputation for the engagement of faculty closely and the teaching, and pay close attention to cost because very likely you're not buying greater quality for the higher sticker price you're being charged. >> one of the things you mentioned, the survey also found that those graduates who carry a lot of student debt when they leave that can very much affect what they do. >> right. i think we've all sensed that student debt is a big, big problem. the survey tells does is an even bigger problem than we thought. that linear fashion, the more debt a student leaves with, even if it's not that much by today's standards, it brings down their so-called well-being across all these dimensions, financial, social, health status and so forth. and another very troublesome finding, the more debt you have, the less likely you are to ever start a business. so that's bad news at the i have level and bad societally and economically. >> miss daniels president of purdue university thin

what we can say is astra shares drop by 2% on the announcement that the board rejected the bid.think a higher offer will be made by pfizer. very,, i would say, it is very difficult to say at this stage. they are working very hard on this one. thank you very much. joining us from geneva. se" is coming up next. we will have a great show. we will not have francine lacqua, but we will have a good show. the flare up in the ukraine. fresh sanctions to be coming up. economic guy will join us. will join us from barcelona for the push into electric taxis. they are doing it in spain. we will talk twitter. the lockout expires today. investors, long-time investors can start to sell the stock. how they will handle the story? this is something that should be priced in. it be a chance for a bubble story? it'll be a great couple of hours. make sure you stay tuned. in the meantime, it's a great event. it happens every year. washington get together to celebrate itself. it is the white house correspondents' dinner. our formal white house correspondent is none other than hans nichols. he has been t